Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues

Immunology

Volumn 123, Issue 3, 2008, Pages 358-366

  Saarelainen, Soili A ^a   Kinnunen, Tuure T ^a   Buhot, Cécile ^b   Närvänen, Ale T O ^a   Kauppinen, Anu K ^a   Rytkönen Nissinen, Marja A ^a   Maillere, Bernard ^b   Virtanen, Tuomas I ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b CEA SACLAY   (France)

Author keywords

Allergen peptide; Cross reactivity; Immunotherapy; Priming; Th2 deviation

Indexed keywords

ALLERGEN; BACTERIAL PROTEIN; BOS ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; LIPOCALIN; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; SEQUENCE ANALYSIS; SPIROPLASMA CITRI; SPLEEN CELL; T LYMPHOCYTE; TH2 CELL;

ALLERGENS; ANIMALS; ANTIGENS, BACTERIAL; CELL PROLIFERATION; CELLS, CULTURED; CROSS REACTIONS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNIZATION; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED STRAINS; PEPTIDE FRAGMENTS; SPIROPLASMA CITRI; SPLEEN; TH2 CELLS;

EID: 38649106431     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02699.x     Document Type: Article

References (44)

1. Åkerstrom B, Flower DR, Salier JP. Lipocalins. Unity in diversity. Biochim Biophys Acta 2000 1482 : 1 8.
2. Virtanen T, Zeiler T, Mäntyjärvi R. Important animal allergens are lipocalin proteins: Why are they allergenic? Int Arch Allergy Immunol 1999 120 : 247 58.
3. Zeiler T, Mäntyjärvi R, Rautiainen J, Rytkönen-Nissinen M, Vilja P, Taivainen A, Kauppinen J, Virtanen T. T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. J Immunol 1999 162 : 1415 22.
4. Saarelainen S, Zeiler T, Rautiainen J, Närvänen A, Rytkönen-Nissinen M, Mäntyjärvi R, Vilja P, Virtanen T. Lipocalin allergen Bos d 2 is a weak immunogen. Int Immunol 2002 14 : 401 9.
5. Immonen A, Saarelainen S, Rautiainen J, Rytkönen-Nissinen M, Kinnunen T, Mäntyjärvi R, Virtanen T. Probing the mechanisms of low immunogenicity of a lipocalin allergen, Bos d 2, in a mouse model. Clin Exp Allergy 2003 33 : 834 41.
6. Jeal H, Draper A, Harris J, Taylor AN, Cullinan P, Jones M. Determination of the T cell epitopes of the lipocalin allergen, Rat n 1. Clin Exp Allergy 2004 34 : 1919 25.
7. Immonen AK, Kinnunen TT, Sirven P et al. The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes. Clin Exp Allergy 2007 37 : 939 47.
8. Saarelainen S, Taivainen A, Rytkönen-Nissinen M et al. Assessment of recombinant dog allergens Can f 1 and Can f 2 for the diagnosis of dog allergy. Clin Exp Allergy 2004 34 : 1576 82.
9. Smith W, Butler AJ, Hazell LA, Chapman MD, Pomes A, Nickels DG, Thomas WR. Fel d 4, a cat lipocalin allergen. Clin Exp Allergy 2004 34 : 1732 8.
10. Virtanen T, Zeiler T, Rautiainen J, Mäntyjärvi R. Allergy to lipocalins. A consequence of misguided T-cell recognition of self and nonself? Immunol Today 1999 20 : 398 400.
11. Kinnunen T, Buhot C, Närvänen A et al. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur J Immunol 2003 33 : 1717 26.
12. Badou A, Savignac M, Moreau M et al. Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-gamma production. Eur J Immunol 2001 31 : 2487 96.
13. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: Amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 2000 164 : 580 8.
14. Brogdon JL, Leitenberg D, Bottomly K. The potency of TCR signaling differentially regulates NFATc/p activity and early IL-4 transcription in naive CD4+ T cells. J Immunol 2002 168 : 3825 32.
15. Ellis RJ, Varela-Calvino R, Tree TI, Peakman M. HLA class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides. Immunology 2005 116 : 337 46.
16. Giovannini M, Braccioni F, Sella G, Contoli M, Perri G, Frati F, Incorvaia C. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study. Allerg Immunol (Paris) 2005 37 : 69 71.
17. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002 360 : 47 53.
18. Westritschnig K, Focke M, Verdino P et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, phl p 7. J Immunol 2004 172 : 5684 92.
19. Alexander C, Tarzi M, Larche M, Kay AB. The effect of fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005 60 : 1269 74.
20. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006 36 : 465 74.
21. Texier C, Herve M, Pouvelle S, Menez A, Maillere B. On the diversity and heterogeneity of H-2(d)-restricted determinants and T cell epitopes from the major bee venom allergen. Int Immunol 1999 11 : 1313 26.
22. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, Sette A. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001 194 : 833 46.
23. Immonen A, Farci S, Taivainen A et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J Immunol 2005 175 : 3614 20.
24. Kinnunen T, Taivainen A, Partanen J, Immonen A, Saarelainen S, Rytkönen-Nissinen M, Rautiainen J, Virtanen T. The DR4-DQ8 haplotype and a specific T cell receptor vbeta T cell subset are associated with absence of allergy to Can f 1. Clin Exp Allergy 2005 35 : 797 803.
25. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995 182 : 1579 84.
26. Foucras G, Gallard A, Coureau C, Kanellopoulos JM, Guery JC. Chronic soluble antigen sensitization primes a unique memory/effector T cell repertoire associated with th2 phenotype acquisition in vivo. J Immunol 2002 168 : 179 87.
27. Guery JC, Galbiati F, Smiroldo S, Adorini L. Selective development of T helper (th) 2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice. J Exp Med 1996 183 : 485 97.
28. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995 181 : 1569 74.
29. Croxford JL, Ercolini AM, Degutes M, Miller SD. Structural requirements for initiation of cross-reactivity and CNS autoimmunity with a PLP139-151 mimic peptide derived from murine hepatitis virus. Eur J Immunol 2006 36 : 2671 80.
30. Ercolini AM, Ludovic Croxford J, Degutes M, Miller SD. Cross-reactivity between peptide mimics of the immunodominant myelin proteolipid protein epitope PLP139-151: Comparison of peptide priming in CFA vs. viral delivery. J Neuroimmunol 2007 186 : 5 18.
31. Kinnunen T, Jutila K, Kwok WW et al. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol 2007 119 : 965 72.
32. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: result of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 6 : 1167 75.
33. Alleva DG, Gaur A, Jin L et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immudominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002 5 : 2126 34.
34. Ise W, Totsuka M, Takato R et al. Primary response of naive CD4(+) T cells to amino acid-substituted analogs of an antigenic peptide can show distinct activation patterns: Th1- and Th2-type cytokine secretion, and helper activity for antibody production without apparent cytokine secretion. FEBS Lett 2000 465 : 28 33.
35. Tanabe S, Shibata R, Nishimura T. Hypoallergenic and T cell reactive analogue peptides of bovine serum albumin, the major beef allergen. Mol Immunol 2004 41 : 885 90.
36. Alleva DG, Maki RA, Putnam AL et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 2006 63 : 59 69.
37. Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002 104 : 105 14.
38. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001 358 : 1749 53.
39. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire. J Exp Med 2000 191 : 761 70.
40. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001 108 : 311 8.
41. Voskuhl RR, Farris RW 2nd, Nagasato K, McFarland HF, Dalcq MD. Epitope spreading occurs in active but not passive EAE induced by myelin basic protein. J Neuroimmunol 1996 70 : 103 11.
42. Bebo BF Jr., Vandenbark AA, Offner H. Male SJL mice do not relapse after induction of EAE with PLP 139-151. J Neurosci Res 1996 45 : 680 9.
43. Anderson AC, Reddy J, Nazareno R, Sobel RA, Nicholson LB, Kuchroo VK. IL-10 plays an important role in the homeostatic regulation of the autoreactive repertoire in naive mice. J Immunol 2004 173 : 828 34.
44. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 2001 31 : 907 17.